live attenuated mumps vaccine (Jeryl Lynn strain)

Vaccineapproved

Approved

Sep 6, 1966

Clinical trial activity

5 trials · 3 clinical orgs · 1 marketing orgs

Phase 1
1
Phase 2
3
Phase 3
3
Phase 4
0

Earliest trial started Oct 1, 2012 (NCT01712906)

Timeline

1960s

  1. Sep 6, 1966

    Earliest FDA Approval

2000s

  1. Sep 6, 2005

    Merck — First NDA Organization

  2. Sep 6, 2005

    Merck — NDA Secondary Org

  3. Sep 6, 2005

    Merck — NDA Organization

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Mumps virusImmunity, active

    Mumps virus immunity, active

Approval history

  • approvedSep 6, 1966

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • attenuated mumps vaccine
  • live attenuated mumps vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04591405Phase 2/Phase 3 (Phase 3)Oct 12, 2020Chinese Academy of Medical Sciences, Government of China
NCT03133923Phase 2May 1, 2017Chinese Academy of Medical Sciences, Government of China
NCT05065177Phase 3Jan 31, 2016Government of China, Sinovac Biotech Co., Ltd
NCT02692599Phase 3Jan 1, 2016Government of China, Sinovac Biotech Co., Ltd
NCT01712906Phase 1Oct 1, 2012Chinese Academy of Medical Sciences, Government of China
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Government of ChinaGovernment5032012
Chinese Academy of Medical SciencesAcademic/Hospital3332012
Sinovac Biotech Co., LtdFor profit2212016
3 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
MerckFor profitNDA2Sep 6, 2005
MerckFor profitNDASep 6, 2005